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Intra-arterial administration of the angiogenesis inhibitor TNP-470 blocks
liver metastasis in a rabbit model
H Tanaka, H Taniguchi, T Mugitani, Y Koishi, M Masuyama, T Higashida, H Koyama,
Y Suganuma, K Miyata, K Takeuchi and T Takahashi
First Department ofSurgery, Kyoto Prefectural University ofMedicine, Kyoto, Japan.
Summary We evaluated the best route of administration of TNP-470, an angiogenesis inhibitor, by compar-
ing the anti-tumour effects and toxicity following injection via the hepatic artery, the portal vein, or the
jugular vein in a rabbit model of liver metastases. Following the injection of 1 x 106 VX2 carcinoma cells into
the portal vein of rabbits, 50 mg of TNP-470 was injected continuously into the hepatic artery, portal vein, or
jugular vein for 7 days. The number of tumours on the surface of the liver was counted 14 days following the
start of the infusion, and the serum glutamic-oxaloacetic transaminase (GOT), glutamic-pyruvic tran-
saminase (GPT) and total bilirubin concentrations were examined. In addition, a coloured silicon rubber was
injected into the vessels of the liver to visualise the capillary networks around the tumours and assess the
degree of suppression of angiogenesis by TNP-470. The mean number of tumours following intra-arterial
injection (17.5 ± 2.9) was significantly less than the control (237.0 ± 34.0) (P<0.05). The mean numbers of the
tumours following intraportal (89.1 ± 16.0) and intravenous (140.6 ± 31.2) injection were both less than the
controls (215.3 ± 45.5, 284.8 ± 55.4 respectively), but the differences were not significant. We conclude that
intra-arterial injection of TNP-470 is the most effective method for preventing liver metastases in this model.
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The prevention of haematogenous metastases, particularly to
the liver, would profoundly improve the prognosis of most
cancer patients. However, it is not yet known how to prevent
or treat liver metastases. Chemotherapy usually is given for
unresectable liver metastases, but several tumours are not
sensitive to drugs currently available. Furthermore, most
tumours develop resistance, and the toxicities of several
agents are too great to permit prolonged treatment.
Because angiogenesis is essential for the proliferation of
cancer cells, the inhibition of new blood vessel growth may
be a useful way to prevent liver metastases (Ingber et al.,
1990). In addition, endothelial cells do not proliferate in
adults except in a few parts of the genital organs (Kusaka et
al., 1991). Therefore, if one could inhibit the endothelial
proliferation selectively, one could suppress tumour growth.
A new synthetic analogue of fumagillin isolated from Asper-
gillus fumigatus, TNP-470, is known to inhibit angiogenesis
by inhibiting DNA synthesis in endothelial cells selectively,
and to have an anti-tumour effect (Ingber et al., 1990;
Kusaka et al., 1991). We have already reported that intermit-
tent intravenous injections of TNP-470 suppress the growth
of VX2 tumour metastases in the livers of rabbits. In that
study, the earlier TNP-470 was injected, the more effectively
the liver metastases were suppressed (Suganuma et al., in
press). The purpose of the current study was to establish the
best route of administration of TNP-470. We hypothesised
that intra-arterial injection and intraportal injection would
suppress liver metastases more effectively than would int-
ravenous injection of this agent, based on our previous
experiments with agents such as 5-fluorouracil (5-FU)
(Takeuchi et al., 1994). In addition, we visualised the small
vessels generated around the liver tumours with a silicon
rubber, to examine the angiogenesis inhibiting activity of
TNP-470.
Materials and methods
TNP-470 [O-(chloroacetyl-carbonyl)fumagilol] was obtained
from Takeda Chemical Industries, Osaka, Japan. Thirty-four
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Japanese white rabbits weighing 2.0-3.0 kg were used for
this study. VX2 carcinoma cells were maintained in the
spleens of rabbits. VX2 tumours were broken into fine pieces,
filtered through a stainless steel mesh, and suspended in
Hanks' balanced salt solution (HBSS). The rabbits were
anaesthetised by pentobarbital sodium (30 mg kg-') which
was given intravenously and subjected to laparotomy. VX2
carcinoma cells (1.0 x 106) in 0.5 ml of HBSS were inoculated
into the superior mesenteric vein to cause liver metastases.
An ALZET osmotic pump, model 2ML1 (Alza Corporation,
CA, USA), was used for the continuous infusion of TNP-
470. The pump has a 2 ml capacity and can infuse an agent
at a constant rate (10 lh-') for 7 days. A 50 mg aliquot of
TNP-470 was dissolved in 2 ml of distilled water. Two ml of
distilled water alone was used as a control.
The 34 rabbits were classified into three groups. The first
received TNP-470 via the jugular vein (group TV: five rab-
bits), with a control group (group CV: five rabbits). A
polyethylene catheter 1.22 mm in diameter (Becton Dickinson
Labware, NJ, USA) was cannulated into the left jugular vein
for both groups. Group TV received 50 mg of TNP-470 over
7 days (about 2.85 mg kg-' day-'), group CV received only
2 ml of distilled water into the vein over 7 days. The second
group received TNP-470 via the portal vein (group TP: seven
rabbits), with appropriate controls (Group CP: six rabbits).
A 1.22 mm polyethylene catheter was inserted into the
superior mesenteric vein and fitted with an ALZET pump.
Group TP received 50 mg of TNP-470, and Group CP dis-
tilled water.
The third group received TNP-470 via the hepatic artery
(group TA: eight rabbits), with controls, (group CA: seven
rabbits). The polyethylene catheter was cannulated into the
common hepatic artery from the left gastric artery, and the
pump was attached. Group TA received 50 mg of TNP-470
into the hepatic artery, and group CA 2 ml of distilled
water.
Fourteen days following the start of the infusion, blood
was taken and analysed for serum GOT, GPT and total
bilirubin concentrations. After being weighed, the rabbits
were killed, and the number of tumours on the surface of the
liver were counted macroscopically.
Just before being killed, each rabbit received 500 units kg-'
heparin intravenously. Immediately following this, the liver
was removed from the fresh cadaver, the portal vein and
hepatic artery were exposed and cannulated withpolyethylene catheters. Microfil (Canton Bio-Medical Prod-
ucts, Boulder. CO, USA) was injected through the catheters
until the vessels appeared well filled. Orange Microfil (MV-
117) was used for the hepatic artery, and yellow (MV-122)
was used for the portal vein (Lin et al., 1984). Low infusion
pressures were used to prevent extravasation of the Microfil.
The specimens were refrigerated overnight to cure the
Microfil. A part of each specimen was fixed in 10% formalin,
sectioned at the maximal diameter of the tumours and
stained by hematoxylin-eosin for histological examination.
The number of vessels inside or around the tumours was then
counted. The remainder of each specimen was immersed
sequentially in 25%, 50%, 75%, 95%, and absolute ethanol
for 1-2 days each, and finally immersed in methylsalicylate.
The specimens became transparent and the vessels' structure
could be examined visually with a stereoscope.
All data are expressed as means ± standard errors. The
results were analysed by Student's t-test. A P-value 0.05
was considered statistically significant.
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Figre I The number of tumours on the surface of each liver
was counted macroscopically. The vertical lines show the 95%.
confidence limits. The number of tumours in the TA group was
significantly less than the number of tumours in the CA group
(P<0.05).
0.3
0.25-
:~ 0.2
0.15
0.1
TV CV TP CP TA CA
Fiure 2 Weight loss between the day of inoculation and 14
days later. There were no significant differences among the
groups.
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Results
The mean number of tumours in group TA (17.5 ± 2.9) was
significantly less than the number of tumours in the controls
(237.0 ± 34.0) (P<0.05). The mean number of tumours in
group TP (89.1 ± 16.0) and group TV (140.6 ± 31.2) were
less than in the respective controls (215.3 ± 45.5.
284.8 ± 55.4), but were not significantly so. The mean
number of tumours in Group TA was significantly less than
in group TP or group TV (P<0.05) (Figure 1). None of the
TNP470 injection groups (TA: 0.16 ± 0.02 kg, TP:
0.12 ± 0.03 kg. TV: 0.19 ± 0.03 kg) exhibited significant
weight loss compared with the controls (CA: 0.20 ± 0.03 kg.
CP: 0.05 ± 0.01 kg, CV: 0.13 ± 0.04 kg (Figure 2). The serum
GOT and GPT concentrations were not higher in the TNP-
470 injected groups than in the controls (Figures 3 and 4).
The total bilirubin was not elevated in any rabbit (Figure 5).
Investigation under a stereoscope of the livers filled with
Microfil revealed networks of vessels around tumours that
originated mainly from the hepatic artery regardless of
tumour size. The larger the tumour became, the more closely
vessels grew around the tumour. However, the vessels around
the tumours of the rabbits that received TNP470 were less
close than the vessels around similar sized tumours in the
controls (Figure 6). Under histological examination, black
material (Microfil) was observed in vessels, which were par-
ticularly dense around the tumours (Figure 7). Microfil was
rarely seen in sinusoid, p-robably because it is too viscous to
get into the sinusoid. No vessel was visible inside tumours
less than 0.25 mm in diameter. Peripheral small necrotic
areas and central necrosis were observed in some of the
tumours over 1.75 mm in diameter in the TNP-470 injected
groups and over 2.5 mm in diameter in the control groups.
Most tumours over 4 mm in diameter had a large central
necrotic zone.
Forty-one small metastases in the TP group and 38 in the
CP group were examined for evaluation of capillary density.
All of them were 0.25-4 mm in diameter because tumours of
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Figre 4 The serum glutamic-pyruvic transaminase (GPT) con-
centration 14 days following the start of infusion. There were no
significant differences in the mean GPT concentration between
the TNP-470 groups and the controls.
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Fgre 3 The serum glutamic-oxaloacetic transaminase (GOT)
concentration 14 days following the start of infusion. The mean
GOT concentration in rabbits that received TNP-470 was not
higher than that of the controls.
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Figue 5 The serum total bilirubin concentrations on the 14th
day. No rabbit had a bilirubin over 1.0mg dl-'.
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F re 6 Microfil filling the hepatic artery. The capillary networks around the tumours of the TA group (upper panels) were less
dense than those of the controls (lower panels). Magnification x 6.6.
other sizes were unsuitable for counting the number of
vessels inside the tumours. The number of cavities which
were filled with Microfil and existed less than 0.25 mm from
the tumour's edge and the number of cavities inside the
tumours were counted individually. The number of
peripheral (84.2 ± 9.2) and interior vessels (49.5 ± 7.1) of the
TNP-470 injected group were significantly less than those of
the controls (126.5 ± 12.2 and 99.2 ± 11.7) (Figure 8).
We suggested that the differences in the density of the
capillary networks between the TNP470 injected groups and
the controls was caused by the angiogenesis inhibiting
activity of TNP470.
Discus
Kusaka et al. (1991) have reported that a broad range of
concentrations of TNP470, which is a synthetic analogue of
fumagillin, a natural product of Aspergillus fumigatus, could
selectively inhibit endothelial proliferation, with a subsequent
anti-tumour effect. Several papers have previously described
the anti-tumour effects of TNP470, but most of them used a
single systemic bolus injection of TNP470 (Toi et al., 1993:
Yanase et al.. 1993).
As TNP470 is cleared rapidly from the serum, we
hypothesised that a continuous infusion of the drug would be
more effective than intermittent administration. In spite of
our expectations, continuous venous injection was no better
than the intermittent injection reported previously. Today,
chemotherapy for liver metastases is often administered
through the hepatic artery. However, there is some evidence
that in the first stage of metastasis, microemboli of tumour
cells are nourished from the portal vein. It is controversial
therefore whether the best route of administration of drugs
to treat liver metastases is the portal vein or from the hepatic
artery. In this study, the mean number of tumours in the
intra-arterial injection group was significantly less than in the
controls. The mean number of tumours in the intraportal
and intravenous groups was less than in the controls, but the
Fiure 7 Microfil was filled
tumours. and is seen in
cation x 40.
into the vessels around and inside
black in this figure. Magnifi-
differences were not significant. Almost all the tumours were
within 7 mm in diameter. with a few tumours in both the
treated groups and control groups over 10 mm in diameter
(maximum 15 mm). Although we expected the tumours to be
smaller in the groups receiving TNP-470, this was not the
case. We do not know why a few tumours in the treated
groups could grow so large, but one hypothesis is that the
agent is not delivered homogeneously into the entire liver.
The current study indicates that arterial injection is the
most effective route for treatment with TNP470. which is
different from our previous report using 5-FU for the same
experimental liver metastases (Takeuchi et al.. 1994). In that
study, continuous arterial and portal infusion of 5-FU were
both more effective than systemic venous infusion, but there
was no significant difference between arterial and portal
administration of 5-FU. What caused this difference? Ter-T-
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Fugwe 8 Both the number of peripheral (a) (84.2 ± 9.2) and interior (b) (49.5 ± 7.1) vessels of the TNP-470 injected group were
significantly less than those of the controls (126.5± 12.2 and 99.2± 11.7).
minal hepatic arterioles and portal venules communicate in
the periportal zone (Rappaport's zone 1) and tumour cells
trapped in sinusoid (Rappaport's zone 2) are nourished by
mixed blood (Lautt et al., 1987). This was thought to explain
the lack of difference between arterial and portal injection of
5-FU. On the other hand, the target of TNP-470 is not the
tumour cell itself, but rather the endothelial cell of tumour-
induced vessels originating from arterioles outside Rappaport's
zone 1 (Lautt et al., 1987). The target endothelium is exposed
to high concentrations of TNP-470 only through the artery.
When TNP-470 is injected through the portal vein, the
tumour cells in the sinusoid are exposed to high concen-
trations of TNP-470, but the endothelium of the periportal
arteriole is exposed to only a small amount of TNP-470
which is delivered following recirculation. That may explain
why the intra-arterial injection of TNP-470 suppressed the
liver metastases most effectively. In other words, our results
are further evidence that the target of TNP-470 is not the
tumour cell itself, but rather the endothelium of arterioles
feeding the tumour.
In our Microfil models, almost all of the tumour vessels
orginated from the hepatic artery, and never from the portal
vein. The number of vessels induced by tumours in the
TNP-470 groups was much less than in the control groups,
which again suggests that the anti-tumour effect of TNP-470
was secondary to the suppression of angiogenesis.
We evaluated the side effects of TNP-470 using weight
loss, and serum GOT, GPT, and total bilirubin elevations as
parameters. None of the TNP-470 injection groups had
significant weight loss or significant liver disfunction com-
pared with the controls. Therefore, the continuous administ-
ration of TNP-470 seems to have no severe adverse
effects.
We conclude that the efficacy of TNP-470 is enhanced by
intra-arterial administration.
Refereces
INGBER D, FUJITA T, KISHIMOTO S. SUDO K, KANAMARU T.
BREM H AND FOLKMAN J. (1990). Synthetic analogues of
fimaillin that inhibit angiogenesis and suppress tumour growth.
Natre, 348, 555-557.
KUSAKA M, SUDO K, FUJITA T. MARUI S, ITOH F, INGBER D AND
FOLKMAN J. (1991). Potent anti-angiogenic action of AGM-
1470: comparison to the fumagillin parent. Biochem. Biophys.
Res. Commnun., 174, 1070-1076.
LAUIT WW AND GREENWAY CV- (1987). Conceptual review of the
hepatic vascular bed. Hepatology, 7, 952-%3.
UN G, LUNDERQUIST A, HAGERSTRAND I AND BOIISEN E.
(1984). Postmortem examination of the blood supply and vas-
cular pattern of small liver metastases in man. Surgery, 96,
517-526.
SUGANUMA Y, TANIGUCHI H, TANAKA H AND TAKAHASHI T.
(1995). Inhibitory effect of anti-angiogenic agent TNP-470
(AGM-1470) on liver metastases of VX2 carcinoma in rabbits.
Regional Cancer Treatment (in press).
TAKEUCHI K. TANIGUCHI H, TANAKA H, AND TAKAHASHI T.
(1994). Experimental study on the continuous infusion of 5-
fluorouracil aginst VX2 tumours metastasizing to the liver of
rabbits. J. Kyoto Pref. Univ. Med., 103, 913-921.
TOI M, YAMAMOTO Y. IMAZAWA T, TAKAYANAGI T, AKUTU K
AND TOMNAGA T. (1993). Antitumor effect of the angiogenesis
inhibitor AGM-1470 and its combination effect with tamoxifen in
DMBA induced mammary tumors in rats. Int. J. Oncol., 3,
525-528.
YANASE T, TAMURA M, FUJITA K, KODAMA S AND TANAKA K.
(1993). Inhibitory effect of angiogenesis inhibitor TNP-470 on
tumor growth and metastasis of human cell lines in vitro and in
vivo. Cancer Res., 53, 2566-2570.